Abstract:Inspired by the lysosomal swelling caused by excessive accumulation of undegraded substances, a lysosomal‐targeting aggregated nanoparticle (LTANP) is synthesized for cancer treatment. By rationally engineering surface properties and interparticle interactions, LTANP enables targeted aggregation in lysosomes of cancer cells, leading to unrelievable lysosomal swelling, and ultimately selectively inducing lysosomal membrane permeabilization and immunogenic cell death of cancer cells. Nanotechnology has proven its enormous application value in clinical practice. However, current research on nanomedicines mainly focuses on developing nanoparticles as delivery carriers to maximize the bioavailability of therapeutic agents, with little attention on exploring their potential to directly regulate physiological processes. In this study, inspired by the lysosomal swelling caused by excessive accumulation of undegraded substances, this work presents a lysosomal‐targeting aggregated nanoparticle (LTANP) for cancer treatment. By rationally engineering surface composition, properties, and interparticle interactions, LTANP achieves efficient tumor accumulation and selective targeted aggregation in lysosomes of cancer cells, leading to unrelievable lysosomal swelling, and ultimately inducing lysosomal membrane permeabilization (LMP) of cancer cells. Further analysis shows that nanoparticle aggregation‐mediated LMP can effectively trigger immunogenic cell death (ICD) by impairing autophagy‐lysosome pathway, evoking robust antitumor immune responses and reversing tumor immunogenicity from "cold" to "hot" in a melanoma model. Additionally, LTANP can combine with clinically approved programmed death ligand‐1 (PD‐L1) antibodies to further unleash T cell‐mediated antitumor immunity, significantly enhancing antitumor performance, inhibiting tumor recurrence and metastasis. This work demonstrates the potential of rationally engineered nanostructures in directly combating cancer and provides novel insights for the development of advanced nanoparticle‐based cancer treatment.

The significance of targeting lysosomes in cancer immunotherapy

Proteasomal and Lysosomal Degradation for Specific and Durable Suppression of Immunotherapeutic Targets

Lysosome Targeted Nanoparticle Aggregation Reverses Immunosuppressive Tumor Microenvironment for Cancer Immunotherapy

Lysosome as the Black Hole for Checkpoint Molecules

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Lysosomes in Cancer—At the Crossroad of Good and Evil

Dual Role of Lysosome in Cancer Development and Progression

Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives

Lysosomes as a Target of Anticancer Therapy

Nanomaterials Respond to Lysosomal Function for Tumor Treatment

Targeted Mevalonate Pathway and Autophagy in Antitumor Immunotherapy

Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential

The Lysosome in Malignant Melanoma: Biology, Function and Therapeutic Applications

Crosstalk between lactate and tumor-associated immune cells: clinical relevance and insight

Recent Progress in the Therapeutic Modulation of Lactate for Cancer Treatment

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer

Targeting the MHC-I endosomal-lysosomal trafficking pathway in cancer: From mechanism to immunotherapy

Lysosomes, curcumin, and anti-tumor effects: how are they linked?

From metabolic byproduct to immune modulator: the role of lactate in tumor immune escape

Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy